Clinical trials - 2008

Trials completed

Phase I

• HVTN 042 (VEE, gag C), commenced November 2003, developed by Alphavax, sites: Johannesburg and Durban, PIs: Glenda Gray and Andrew Robinson.
• IAVI 001 (MVA), commenced November 2003, developed by IAVI, sites: Johannesburg and Durban, PIs: Eftyhia Vardas, Glenda Gray, Andrew Robinson.
• HVTN 050 (Ad5, gag B), commenced October 2004, developed by Merck, site: Johannesburg, PI: Glenda Gray.
• HVTN 059 (VEE, gag C), commenced April 2004/2005, developed by Alphavax, sites: Johannesburg and Durban, PIs: Glenda Gray, Andrew Robinson.

Phase II

• IAVI A002 (AAV), commenced November 2005, developed by Targeted Genetics, sites: Johannesburg, Medunsa, Cape Town, PIs: Eftyhia Vardas, Linda-Gail Bekker and Anwar Hoosen.

Phase IIb

• HVTN 503 (MRK Ad 5 polyvalent B), sponsored by HVTN, commenced February 2007, 3000 participants, sites: Johannesburg, Cape Town, Durban, Medunsa and North West Province, National PI: Glenda Gray. Stopped in October 2007.

Trials in progress

Phase II

• FIT Biotech DNA therapeutic vaccine, commenced April 2006, developed by FIT Biotech Plc, Phase II, site: Perinatal HIV Research Unit, Chris Hani Baragwanath, PI: Eftyhia Vardas.
• HVTN 204 (DNA/Ad5 ABC), commenced August 2006, developed by the Vaccine Research Center, sites: KOSH Johannesburg, Cape Town, PIs: Gavin Churchyard, Glenda Gray and Linda-Gail Bekker.

Trials planned

Phase I

• SAAVI 102/HVTN 073 DNA/MVA phase I trial – currently at the Medicines Control Council.

About

SAAVI partners and activities

SAAVI funded projects 2006-2009

Clinical trials completed, in progress and planned